Novel fumarate analog XP23829 for RRMS begins phase I trial

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Novel fumarate analog XP23829 for RRMS begins phase I trial

Postby MSUK » Mon Jul 23, 2012 10:48 pm


XenoPort, Inc. has announced that the first subjects have been dosed in a Phase 1, randomized, double-blind, two-period crossover, food effect comparison study of XP23829 in healthy adults. The trial is designed to assess the pharmacokinetics, safety and tolerability of a single dose of XP23829 administered in both fasted and fed conditions.

Approximately 60 subjects will be assigned to one of five cohorts with each cohort receiving one of four different formulations of XP23829 or placebo. Subjects will receive a single dose of XP23829 or placebo in both a fasted and fed state in randomized order. The trial will assess the blood levels of XP23829, its active metabolite, monomethyl fumarate (MMF), and other potential metabolites. The four XP23829 formulations will include one immediate-release formulation and three extended-release formulations that are designed for possible once-a-day dosing of XP23829.

Ronald W. Barrett, Ph.D., chief executive officer of XenoPort, said, "Dosing of the first human subject with XP23829 is an important milestone as we work to develop this potential best-in-class fumarate analog. One goal of this study is to verify that XP23829 is efficiently metabolized to produce MMF in the blood. We believe that the MMF pharmacokinetic profiles produced by the different XP23829 formulations administered with and without food will be instructive for the selection of one or more formulations to take forward into future trials."... Read More - ... ageid/1397
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm


Return to General Discussion


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service